TNFRSF1B and neoplasm: Treatment with anti-OX40 mAb impaired the function of Treg cells and enhanced Teff cell responses, resulting in increased anti-tumor immunity and improved tumor-free survival.823 Thus, TNFR2 is a potential target for the development of Treg cell-based immunomodulatory therapies.